Last reviewed · How we verify

NCT01387802: Complete-AS

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis

Completed Last updated 9 December 2020
What this trial tests

trial in Ankylosing Spondylitis in 722 participants. Completed in 16 December 2019.

Timeline
29 June 2011
Primary endpoint
16 December 2019
16 December 2019

Quick facts

Lead sponsorAbbVie (prior sponsor, Abbott)
StatusCompleted
Study typeOBSERVATIONAL
Enrollment722
Start date29 June 2011
Primary completion16 December 2019
Estimated completion16 December 2019
Sites56 locations across Canada

Conditions studied

Sponsor

AbbVie (prior sponsor, Abbott) — full company profile →

Who can join

Adults 18 to 99, any sex, with Ankylosing Spondylitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study will assess the real - life effectiveness of adalimumab in the management of Ankylosing Spondylitis (AS) with emphasis on the prevention and management of extra-articular manifestations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Ankylosing Spondylitis

Currently open trials in the same condition.

Other AbbVie (prior sponsor, Abbott) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01387802.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing